white → purple2 → black3 → black3 → black3 → black3
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
MDEA
3,4-Methylenedioxy-N-ethylamphetamine
MDE, EveOpen in Piru
MDEA is a synthetic entactogen and stimulant of the substituted amphetamine class1, closely related to MDMA and MDA.1 It was introduced for recreational use in the United States in 1985.2 Its effects are generally described as milder and shorter lasting than those of MDMA, with a more sedating quality reported at high doses. MDEA was among the substances found in tablets sold as ecstasy during the mid-1990s.3
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold40 mg
Light80-100 mg
Moderate100-150 mg
Strong150-200 mg
Heavy225+ mg
Duration
Onset20-60 minutes
Come Up15-30 minutes
Peak1.5-2 hours
Offset1-2 hours
After Effects12-48 hours
Total3-6 hours
Subjective Effects
Subjective Effects not written up yet
Reagent Testing
Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.
white → black3 → black3 → black3 → black3
yellow2 → blue2 → black3 → black3 → black3 → black3
white → blue2 → black3 → black3 → black3
Pharmacology
Pharmacodynamics
MDEA promotes the release of serotonin, norepinephrine, and dopamine and inhibits their reuptake, increasing their levels in the brain. Its serotonin-releasing activity is relatively greater than its dopamine-releasing activity.1 MDEA also stimulates the release of oxytocin, prolactin, and antidiuretic hormone.
Pharmacokinetics
Absorption & half-lifenot documented yetMetabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Tolerance to many of MDEA's effects develops with prolonged, repeated use. Empathic effects may diminish substantially while stimulation and euphoria remain, with some users reporting loss of empathic qualities after as few as 10 experiences and others only after hundreds of uses. Some users report no decline in experience quality despite dozens or hundreds of uses.
Tolerance returns to baseline after approximately 2–3 months, provided no further MDEA is consumed.
Tolerance takes approximately 1–1.5 months to decrease by half, provided no further MDEA is consumed.
Dopaminergic stimulants, Serotonergic stimulants, Entactogens
Harm Potential
Addiction & Dependence
Psychological
ModerateWith ongoing use, MDEA may produce moderate addiction risk, substantial abuse potential, and psychological dependence in some users. After dependence has formed, abrupt cessation can be followed by cravings and withdrawal effects.
Physical
LowPhysical dependence is not prominently characterized, though withdrawal effects including cravings may occur with chronic use.
Toxicity
Repeated or high doses of MDEA are likely to carry neurotoxic risk. As a potent serotonin releaser, it is believed to reduce serotonin reuptake transporter availability in the brain, and the timeline for recovery remains uncertain.
Heavy MDEA use over extended periods is likely to harm the cardiovascular system and may contribute to valvulopathy; overdose-level exposure can produce acute tachycardia and hypotension.
MDEA and related compounds are hepatotoxic; regular use may cause liver damage.
Hyperthermia is a significant acute risk, particularly with continuous activity without sufficient rest or rehydration; body temperature may rise to dangerous levels.
Overdose may cause muscle rigidity and rhabdomyolysis.
Psychosis Risk
Regular use may lead to schizophrenia-like symptoms according to available sources.
Seizure Risk
Convulsions are listed among overdose symptoms. Risk may be increased when combined with substances that lower seizure threshold.
History & Culture
Alexander Shulgin researched methylenedioxy compounds during the 1960s.4 In a 1967 laboratory notebook entry, he briefly recorded a colleague's report of having experienced no effect from MDEA. Its synthesis and pharmacological evaluation, alongside related…
Legality
International
MDEA (N-ethyl MDA) is listed in Schedule I of the 1971 Convention on Psychotropic Substances. It is not named in the schedules of the 1961 Single Convention, and it is not one of the precursor chemicals in Tables I or II of the 1988 Convention; those latter instruments therefore do not independently schedule/control exact MDEA.
By Country
Illegal28
United StatesIllegalMDEA is expressly listed in Schedule I as 3,4-methylenedioxy-N-ethylamphetamine. Federal law prohibits unauthorized manufacture, distribution, dispensing, and possession of Schedule I controlled substances.
By state
GuamIllegal
IowaIllegalIowa Code § 124.204(4)(aa) expressly lists 3,4-methylenedioxy-N-ethylamphetamine and identifies N-ethyl MDA, MDE, and MDEA as aliases. Schedule I substances are controlled substances under § 124.101(5). Unauthorized manufacture, delivery, possession with intent to manufacture or deliver, and knowing or intentional possession are prohibited under § 124.401(1) and (5); the reviewed provisions contain no MDEA-specific exception, while § 124.401 retains its general authorization and valid-practitioner-prescription/order language.
OhioIllegalOhio Admin. Code 4729:9-1-01.88
Ohio's current Board of Pharmacy schedule directly lists the exact substance and aliases.
UtahIllegalUtah Code § 58-37-8(1)(a)(ii)(N)89
Utah expressly lists the exact substance and aliases.
IdahoIllegalIdaho Code § 37-2705(d)90
Idaho expressly lists the exact substance and the N-ethyl MDA, MDE, and MDEA aliases.
MaineIllegal17-A M.R.S. § 1102(1)(O)(11)91
Maine expressly lists exact MDE, but uses its Schedule W classification rather than federal Schedule I nomenclature.
TexasIllegal
AlaskaIllegalAlaska Stat. § 11.71.150(e)(7)94
Alaska expressly lists the exact substance as ‘3,4-methylenedioxy-N-ethylamphetamine,’ with the aliases N-ethyl MDA, MDE, and MDEA, in Schedule IIA’s stimulant list. Alaska’s controlled-substance offenses prohibit unauthorized possession, manufacture, and delivery of Schedule IIA substances; the listing is not a prescription-availability finding. The recovery lead’s ‘hallucinogenic substance’ designation is not retained because subsection (e) is the Schedule IIA stimulant list.
HawaiiIllegalHaw. Rev. Stat. § 329-14(d)(7)95
Hawaii expressly names the exact substance and uses MDE as its parenthetical alias; separately listed bk-MDEA/ethylone is not relied upon.
NevadaIllegalNev. Admin. Code 453.510.96
Nevada's current administrative Schedule I expressly lists the exact substance and aliases.
OregonIllegalOregon incorporates federal Schedules I-V into its controlled-substance definition, subject to ORS 475.035. The current federal Schedule I list expressly identifies the exact substance and aliases. Except as authorized, Oregon prohibits manufacture or delivery; knowing or intentional possession is prohibited unless obtained pursuant to a valid practitioner prescription/order or otherwise authorized. Oregon registration and DEA-authorized research provisions provide limited lawful pathways; ORS 475.924(2)(c) is retained only as an Ecstasy definition for ORS 475.907, 475.924 and 475.925 sentencing context, not as the classification basis. Oregon also expressly names MDEA in enhanced possession and sentencing-quantity provisions (ORS 475.874(2)(b)(C), 475.900).
AlabamaIllegalAla. Admin. Code r. 420-7-2-A, Schedule I(d)(12) (Appendix Controlled Substances List)98
Alabama's current official Appendix Controlled Substances List expressly identifies 3,4-methylenedioxy-N-ethylamphetamine as N-ethyl MDA, MDE, and MDEA in Schedule I(d)(12). The Schedule I(d) lead-in covers any material, compound, mixture, or preparation containing any quantity of the listed substance and covered salts and isomers, unless specifically excepted or listed in another schedule.
ArizonaIllegalArizona expressly lists 3,4-methylenedioxy-N-ethylamphetamine, the federal listing's MDE/MDEA and N-ethyl MDA, as a dangerous drug and hallucinogenic substance. A.R.S. § 13-3407(A) prohibits knowing possession or use, possession for sale, manufacturing-related possession and manufacture, administration, fraudulent procurement of administration, and sale, transfer, or specified transport/import conduct. The definition applies unless specifically excepted; no MDEA-specific exception appears in the listed provision.
FloridaIllegalFla. Stat. § 893.03(1)(c)(26)101
Florida expressly lists MDEA with its exact chemical name in the Schedule I hallucinogen list.
IndianaIllegalIndiana expressly lists the exact substance 3,4-methylenedioxy-N-ethylamphetamine (MDEA) in Schedule I as a hallucinogenic substance. Indiana Code § 35-48-4-7 prohibits knowing or intentional possession of a Schedule I controlled substance subject to that section's terms; its express Schedule I possession exception is for marijuana, hashish, or salvia, not MDEA. No MDEA-specific exception appears in the Schedule I listing.
MontanaIllegalMont. Code Ann. § 50-32-222 (Schedule I); current-session enrolled bill reproducing the state schedule.103
Montana expressly names the exact substance and aliases in its Schedule I hallucinogen list; this is direct state scheduling, not an analogue or incorporation inference.
ArkansasIllegalArkansas Department of Health, Rules Pertaining to the List of Controlled Substances104
The Arkansas Department of Health's current published controlled-substances rule expressly lists the exact chemical 3,4-methylenedioxy-N-ethylamphetamine and identifies N-ethyl MDA, MDE, and MDEA as alternate names. The Schedule I hallucinogenic-substances provision covers any material, compound, mixture, or preparation containing any quantity of a listed substance, including applicable salts and isomers, unless specifically excepted or listed in another schedule. The primary-source listing supports the allowed canonical status prohibited.
ColoradoIllegalColo. Rev. Stat. § 18-18-203105
Colorado's Schedule I list expressly includes MDEA/N-ethyl MDA.
IllinoisIllegalIllinois expressly lists the exact substance, rather than regulating it only as an analog. The Act makes knowing possession unlawful except as otherwise authorized, and likewise prohibits knowing manufacture, delivery, or possession with intent to manufacture or deliver except as authorized. Illinois licensing may authorize manufacture, distribution, or dispensing of controlled substances in Section 204; a Schedule I or II registrant is limited to substances specified in its registration. Section 401 separately excludes conduct conforming to an approved federal new-drug application or investigational-use exemption.
KentuckyIllegalKRS § 218A.070110
Kentucky's Schedule I list expressly includes 3,4-methylenedioxy-N-ethylamphetamine (MDEA).
MissouriIllegalMo. Rev. Stat. § 195.017(2)(5)(u)111
Missouri expressly lists the exact substance.
NebraskaIllegalNeb. Rev. Stat. § 28-405(c)(30)(xxxvi).112
Nebraska's enumerated Schedule I list expressly identifies the exact substance and aliases.
New YorkIllegalN.Y. Pub. Health Law § 3306, Schedule I(d).113
New York directly enumerates the exact substance and aliases in the Schedule I hallucinogenic-substance list (with the statutory spelling 'methylendioxy').
VirginiaIllegalVa. Code § 54.1-3446114
Virginia expressly lists the exact substance and aliases in Schedule I.
LouisianaIllegalLa. R.S. § 40:964(Schedule I)(C)115
Louisiana's Schedule I hallucinogen list expressly includes 3,4-methylenedioxy-N-ethylamphetamine (MDEA).
MinnesotaIllegalMinn. Stat. § 152.02, subd. 2(d)(3)116
Minnesota expressly lists MDEA.
TennesseeIllegal
WisconsinIllegalWisconsin expressly places this exact substance in Schedule I. The federal Schedule I entry identifies 3,4-methylenedioxy-N-ethylamphetamine as N-ethyl MDA, MDE, and MDEA, supplying the exact identity bridge. Wisconsin prohibits manufacture, distribution, or delivery except as authorized by ch. 961; the § 961.14 Schedule I list is subject to state/federal exceptions or more-specific scheduling.
CaliforniaIllegal (analog/blanket ban)California's current disjunctive definition is met on chemical structure: PubChem identifies MDEA as 1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine and MDA as 1-(1,3-benzodioxol-5-yl)propan-2-amine; MDEA retains MDA's benzodioxolyl-propan-2-amine scaffold and differs by N-ethyl substitution. This is not a name-only inference. MDA, not MDMA, is the comparator listed in Cal. HSC §11054(d)(6); MDMA has an N-methyl group, while bk-MDEA/ethylone has a beta-ketone, so neither is the substance assessed. Section 11401(a) makes an analog subject to Chapter 6 (commencing §11350), which includes possession (§11377(a)(2)) and transport/sale/furnishing (§11379(a)(2)) for §11054(d) substances. No §11401(c) exclusion is established: MDEA is federally Schedule I (not evidence of an approved/GRAS drug); no person-specific investigational exemption is identified; and the pre-exemption exclusion only applies before such an exemption takes effect and only to non-human-consumption conduct. Application to a particular person remains subject to proof and any actual authorization or exemption.
WashingtonIllegalRCW 69.50.204(c)(12) expressly places the exact substance and aliases in Schedule I. The schedule is subject to substances specifically excepted by state or federal law or regulation or more specifically included in another schedule. Except as authorized by chapter 69.50 RCW, RCW 69.50.401(1) prohibits manufacture, delivery, and possession with intent to manufacture or deliver a controlled substance; RCW 69.50.4013(1) prohibits knowing possession, and public use, subject to its chapter and prescription/order authorization language. PubChem identifies MDEA as 3,4-methylenedioxy-N-ethylamphetamine and N-ethyl MDA as a synonym.
ConnecticutIllegalRegs. Conn. State Agencies § 21a-243-7(c)(5)131
Connecticut's current controlled-substances regulation expressly lists exact MDEA.
North DakotaIllegalN.D. Cent. Code § 19-03.1-05; N.D. Admin. Code ch. 61-13.132
North Dakota's controlled-substance schedule materials expressly name the exact substance and aliases.
PennsylvaniaIllegalControlled Substance, Drug, Device and Cosmetic Act § 13(o), 35 P.S. § 780-113(o).133
Pennsylvania specifically names exact MDEA in a substance-specific provision, rather than relying on an analogue theory or generic conformity.
South DakotaIllegal
West VirginiaIllegalW. Va. Code § 60A-2-204(d)(13)136
West Virginia expressly lists the exact substance and aliases in Schedule I.
North CarolinaIllegalN.C. Gen. Stat. § 90-89(3)d.137
North Carolina expressly places the exact substance and aliases in its Schedule I hallucinogenic-substances list.
ArgentinaIllegalArgentina's current Annex I lists MDE and expressly gives ADAM, MDEA, and N-etil MDA as synonyms; it identifies the substance as N-etil-3,4-metilendioxianfetamina. Decree 560/2019 treats Annex I substances as estupefacientes for article 77 of the Penal Code, while Law 23,737 supplies the separate criminal conduct and penalty rules. The classification does not itself state a prescription or other authorization exception for MDEA.
AustriaIllegalSuchtmittelgesetz (SMG) §2(2), §5, §6, §8 and §27, implemented by Suchtgiftverordnung (SV), Gesetzesnummer 10011053, Annex V.1; Psychotropenverordnung (PV), Gesetzesnummer 10011054, is not the operative schedule because SMG §3/PV cover Convention Annexes III and IV, while N-Ethyl MDA is in Convention Annex I.33343536373839404142
BelgiumIllegalBelgium lists N-ethyl MDA (MDE), chemically (±)-N-ethyl-α-methyl-3,4-(methylenedioxy)phenethylamine, in Annex IIA of the Royal Decree of 6 September 2017. Annex IIA comprises substances in Schedule I of the 1971 Convention on Psychotropic Substances. The decree prohibits importing, exporting, transporting, manufacturing, possessing, selling, supplying, dispensing, or acquiring listed products without an activity authorisation, and limits Annex IIA authorisations to duly authorised persons working in authorised medical or scientific establishments for scientific or very limited medical purposes. Legally obtained medicines and ordinary pharmacist activities are not excepted for Annex IIA substances under the decree's general exemptions.
BrazilIllegalPortaria SVS/MS nº 344, de 12 de maio de 1998, Anexo I, Lista F2 (Lista das Substâncias Psicotrópicas de Uso Proscrito no Brasil), in the current consolidated version maintained by Anvisa; RDC nº 1.036, de 9 de julho de 2026 is identified by Anvisa as the current version and does not alter Lista F2.19202122
CanadaIllegalControlled Drugs and Substances Act23
ChileIllegalChile’s current psychotropic-substances regulation expressly lists N-Etil MDA, the N-ethyl MDA designation for MDEA, in its controlled schedule. The regulation subjects scheduled psychotropic substances to the authorization and control regime administered by the Instituto de Salud Pública. The underlying drug law criminalizes unauthorized production, trafficking, possession, and related conduct involving controlled drugs, while regulated authorization mechanisms are not a general public exception.
FinlandIllegalFinland's current controlled-substances decree expressly lists N-ethyl-3,4-methylenedioxyamphetamine (MDEA). The Narcotics Act prohibits production, manufacture, import, export, transit, distribution, trade, handling, possession, and use of narcotic drugs, subject to the Act's specified medical, scientific, and official-authority permissions.
FranceIllegalArrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants (current consolidated Legifrance text), read with Code de la santé publique, article L. 5132-7.2425
The consolidated arrêté's narcotics list designates the exact N-ethyl-MDA/MDEA substance, not MDMA, MDA, ethylone (bk-MDEA), or another ‘MDE’ abbreviation. Article L. 5132-7 makes production, manufacture, transport, import, export, possession, offer, transfer, acquisition, and use of a scheduled narcotic prohibited. The Code permits only the statutory derogation/authorization route, rather than a general possession or medical-prescription exception.
IndiaIllegalMDEA is listed by its exact synonym, N-ethyl MDA, in the Schedule to the Narcotic Drugs and Psychotropic Substances Act, 1985. Section 8(c) prohibits production, manufacture, possession, sale, purchase, transport, use, consumption, and specified cross-border or inter-State dealings in a psychotropic substance, except for medical or scientific purposes and as provided by the Act, rules, or orders.
IndonesiaIllegalMDEA is expressly listed as N-ETIL MDA in Indonesia's Narkotika Golongan I schedule, with the chemical description (±)-N-Etil-α-metil-3,4-(metilendioksi)fenetilamina. Group I narcotics are not used in therapy and are restricted to scientific-development purposes; the underlying narcotics law prohibits Group I use for health-care services. This classification distinguishes MDEA from the separately listed cathinone ethylone (bk-MDEA).
IrelandIllegal (analog/blanket ban)MDEA/MDE (N-ethyl-MDA) is controlled through Ireland's Schedule 1 phenethylamine structural-definition clause rather than by the abbreviation MDEA. The clause covers a substance structurally derived from an N-alkyl-alpha-methylphenethylamine by ring substitution with an alkylenedioxy group, which describes N-ethyl-3,4-methylenedioxyamphetamine. Unauthorised possession is an offence, and production, supply, importation and exportation are prohibited subject to the statutory regulatory and licensing exceptions.
ItalyIllegalItaly lists MDEA in Table I as 3,4-metilendiossietilamfetamina and identifies MDE and N-etil-MDA as alternative names. Table I substances fall under the DPR 309/1990 controlled-substances regime: unauthorized production, supply, import, export, acquisition or non-personal possession is criminalized, while illicit possession for personal use is subject to administrative sanctions rather than being lawful.
JapanIllegalJapan expressly designates N-ethyl MDA as a narcotic, including its salts, under Article 1(24) of Cabinet Order No. 238. A Ministry of Health, Labour and Welfare regulatory-structure reference identifies this substance as N-ethyl methylenedioxyamphetamine and gives MDE and MDEA as its aliases, distinguishing it from separately listed cathinone substances. The Narcotics and Psychotropics Control Act therefore regulates it as a narcotic; the designation implementation notice describes tightly limited licensed research handling and states that practitioner possession or administration is not permitted as a policy for this substance.
NetherlandsIllegalOpium Act70
MDEA is expressly listed on List I of the Dutch Opium Act as N-ethyl-3,4-methylenedioxyamphetamine (N-ethyl-MDA), with its chemical description. Article 2 prohibits importing, exporting, preparing, processing, selling, supplying, transporting, possessing, and manufacturing List I substances; statutory exemptions and ministerial exemptions can apply in specified circumstances.
New ZealandIllegalMisuse of Drugs Act 197571
N-ethyl MDA is expressly listed in Part 2 of Schedule 2 to the Misuse of Drugs Act 1975, with a chemical description matching MDEA. It is therefore a Class B controlled drug under that Act. Possession, supply, import, export, and other conduct remain governed by the Act's applicable offences, authorities, and exceptions.
PhilippinesIllegalMDEA (N-ethyl-MDA) is a Schedule I psychotropic substance in the 1971 Convention schedule reproduced in the Annex to Republic Act No. 9165. The Act defines substances in that annex as dangerous drugs, and it prohibits unlicensed importation, sale, distribution, transport, manufacture, possession, and use of dangerous drugs. The statutory authorization and practitioner provisions regulate lawful medical or research handling; they do not create a general public exception.
PolandIllegalMinister of Health Regulation on lists26
Poland lists N-Etylo-MDA and MDEA by name in the Group I-P psychotropic-substances schedule. The listing gives the chemical designation (±)-N-etylo-α-metylo-3,4-(metylenodioksy)-fenetyloamina, directly identifying N-ethyl-MDA rather than MDMA, MDA, or ethylone. As a Group I-P psychotropic substance, MDEA is subject to Poland's controlled-substance regime rather than a prescription-availability listing.
RussiaIllegalMDEA (N-ethyl-MDA) is expressly listed in Russia's Schedule I of narcotic drugs, psychotropic substances and their precursors subject to control. Schedule I substances are prohibited from circulation in the Russian Federation, except as the statute permits for research, training, expert and other narrowly authorised purposes.
SingaporeIllegalSingapore lists N-Ethyl-alpha-methyl-3,4-(methylenedioxy)phenethylamine, also known as MDEA, as a Class A controlled drug in First Schedule item 56 of the Misuse of Drugs Act 1973. The Act defines a controlled drug as a substance specified in Part 1, 2 or 3 of that Schedule. Except as authorised by the Act, possession and consumption, trafficking, and import or export of a controlled drug are offences. MDEA is expressly listed rather than controlled through related MDMA, MDA, or bk-MDEA entries.
South AfricaIllegalDrugs and Drug Trafficking Act 140 of 199276
South Africa expressly lists N-ethyl-methylenedioxyamphetamine under methylenedioxyamphetamine (MDA) in Part III of Schedule 2 to the Drugs and Drug Trafficking Act 140 of 1992. Part III defines an undesirable dependence-producing substance, so unauthorised use, possession, and dealing are offences; the Act preserves limited lawful medical, professional, regulatory, and permit-based exceptions. The schedule's coverage also includes specified isomers, esters, ethers, salts, preparations, mixtures, and homologues unless expressly excluded.
SpainIllegalRoyal Decree 2829/197718
Spain lists N-etil MDA, also called MDE or MDEA, in List I of Annex 1 to Royal Decree 2829/1977 and identifies its chemical name as (±)-N-etil-alfa-metil-3,4-(metilenedioxi)fenetilamina. Article 2 prohibits its use, manufacture, import, export, transit, trade, distribution, possession, and inclusion in any preparation. The decree permits scientific use only when the Dirección General de Ordenación Farmacéutica authorizes it case by case and specifies the applicable controls.
SwedenIllegalMDEA (N-ethyl-MDA) is listed by its exact chemical name, N-etyl-3,4-metylendioxiamfetamin (MDEA), in Läkemedelsverket's current narcotics schedules as a Schedule I narcotic. Sweden treats scheduled narcotics as controlled substances: unauthorized possession, use, transfer, manufacture, and non-personal-use handling are criminal offences. Statutory exceptions concern authorized medical, scientific, particularly important public-benefit, or specified industrial purposes; they do not make ordinary possession or use lawful.
UkraineIllegalUkraine expressly lists N-ethyltenamphetamine (MDE, N-ethyl-MDA), with the chemical name (±)-N-ethyl-alpha-methyl-3,4-(methylenedioxy)phenethylamine, in Table I, List No. 2 as a particularly dangerous psychotropic substance whose circulation is prohibited. Table I circulation is prohibited, rather than prescription-only; the law allows List No. 2 circulation only for the statutory expert/operational and licensed educational, scientific, or scientific-technical purposes, not ordinary medical prescription dispensing.
United Arab EmiratesIllegalThe UAE controlled-substances schedule expressly lists MDE, N-ethyl MDA and supplies the corresponding N-ethyl methylenedioxy chemical name. It is classified as a Schedule I psychotropic substance and marked prohibited. The Federal Decree-Law criminalises production, import, export, transport, purchase, sale, possession, and storage of narcotic and psychotropic substances except supervised, regulated medical or scientific activity under applicable law.
United KingdomIllegal (analog/blanket ban)MDEA is a Class A controlled drug because it is an N-alkyl-alpha-methylphenethylamine with a 3,4-methylenedioxy ring substitution, falling within the Act's express phenethylamine-derivative definition. It is also subject to Schedule 1 controls under the Misuse of Drugs Regulations 2001.
Controlled / restricted2
AustraliaRestrictedAustralia's Commonwealth Customs (Prohibited Imports) Regulations 1956 expressly list N-ethyl-methylenedioxyamphetamine, otherwise known as N-ethyl MDA, in Schedule 4. Regulation 5 prohibits importation of a Schedule 4 drug unless the importer holds the required licence and permission and meets the stated conditions. The instrument provides limited import exceptions, including a passenger's prescribed medicine. It governs importation, not the separate domestic possession, supply, or manufacture laws of the States and Territories.
DenmarkRestrictedDenmark's current euphoriant-substances order expressly lists N-ethyl MDA, the exact substance also known as MDEA/MDE, as List B entry 354. List B substances may only be used for medical and scientific purposes. Import, export, sale, receipt, manufacture, processing, possession and other activity are permitted only under the order's specified authorization, prescription, or institutional routes; this is not a general possession exemption.
References
Source Pages
Citations
Further Reading
Freudenmann & Spitzer - The Neuropsychopharmacology and Toxicology of MDEA
Stone et al. 1987 - A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives- Nash & Nichols 1991 - Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues
- Glennon et al. 1988 - Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the MDEA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
